Medical studies and recent lawsuits against the makers of Risperdal have helped highlight the links between the drug and gynecomastia, a condition that causes males to grow breasts.
A 2006 study conducted by Duke University showed that Risperdal was associated with gynecomastia and that it may cause lactation in girls, boys, and women not pregnant or nursing.
Despite this knowledge, the FDA approved Risperdal for the treatment of schizophrenia in children and bipolar disorder in both children and adults in 2007. The year after the FDA approval, the Wall Street Journal reported that Risperdal had been shown to increase prolactin levels (leading to breast development and lactation) and experts stated that up to 70 percent of gynecomastia childhood events were found to be caused by Risperdal use.